Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Julia Eckl-Dorna

Head of Vienna Airway Lab

Medical University of Vienna

Research Interests

Explore related searches

Recent Grants

Understanding mechanisms of allergic symtpom loss with age

Open Date: 2024-09-01

Close Date: 2028-08-31

Articles (20)

Collaborators (6)

Petra Pjevac

Sientific and Operational Director

Universität Wien

Martin Schepelmann

Group Leader / PI

Medical University of Vienna

Heimo Breiteneder

Full University Professor

Medical University of Vienna

Anette Drøhse Kjeldsen

University of Southern Denmark

Mohammed Zghaebi

Senior Researcher

Medical University of Vienna

Sven Seys

Chief Scientific Officer

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Julia Eckl-Dorna

Research Interests

Explore related searches

Recent Grants

Articles (20)

Collaborators (6)

Petra Pjevac

Martin Schepelmann

Heimo Breiteneder

Anette Drøhse Kjeldsen

Mohammed Zghaebi

Sven Seys

Make your next move.

Julia Eckl-Dorna

Research Interests

Explore related searches

Recent Grants

Articles (20)

Germinal center interleukin-4 microniches drive tissue divergence of IgE memory B cell responses

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract-the B Cell Side

Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes

Proteomic profiling and machine learning for endotype prediction in chronic rhinosinusitis

Indication for biologic treatment in a real-world cohort of chronic rhinosinusitis patients according to international recommendations

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients

Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1

Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1 (vol 17, 1864741, 2026)

Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes (Mar, 10.1002/alr.70125, 2026)

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge

Long-term dupilumab therapy reduces concomitant medication use in patients with CRSwNP

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)

Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR

Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)

Transcriptomic Profiles of the Nasal Mucosa Following Birch Pollen Provocation Differ Between Birch Pollen‐Allergic and Non‐Allergic Individuals

[Principles of microbiome research].

Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study.

A second Artemisia pollen peak in autumn in Vienna: reaching the point of no return?

Patient‐reported disease control versus overall symptom severity as global metrics of chronic rhinosinusitis disease status

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)

Collaborators (6)

Petra Pjevac

Martin Schepelmann

Heimo Breiteneder

Anette Drøhse Kjeldsen

Mohammed Zghaebi

Sven Seys

Make your next move.